MedTrace Logo

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-02-04

No results posted yet for this study

Summary

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT

Conditions

Interventions

DRUG

[18F]FP-R01-MG-F2

7mCi (range 6-9mCi) \[18F\]FP-R01-MG-F2 will be administered

Sponsors & Collaborators

Principal Investigators

  • Henry Guo, MD, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2023-04-25
Completion
2025-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03183570 on ClinicalTrials.gov